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ABSTRACT 
Purpose: The association of hyperglycaemia and Diabetic Retinopathy (DR) in established 
type 2 Diabetes Mellitus (T2DM) subjects is well accepted. However the association between 
β-cell responsiveness and insulin sensitivity leading to fasting and postprandial 
hyperglycaemia with DR in newly diagnosed treatment naïve T2DM subjects remain 
unreported.  
Methods: 544 newly diagnosed treatment naïve T2DM subjects were screened for DR 
(digital photography) and underwent a standardised ‘Meal Tolerance Test’. Serial Plasma 
glucose and insulin levels were measured and fasting (M0) and postprandial (M1) β-cell 
responsiveness calculated {CPR (Calculating Pancreatic Response) Program} along with 
HOMA-B and HOMA-S. A subgroup of 201 subjects also underwent  a ‘Frequently Sampled 
Intravenous Glucose Tolerance Test’ and the acute insulin response to glucose (AIRG), 
insulin sensitivity (SI) and glucose effectiveness (SG) estimated (MinMod model).  
Results: 16.5% (90) subjects had DR at diagnosis. Subjects with DR had significantly 
reduced M0, HOMA-B and SG leading to higher fasting and postprandial (2hour) glucose and 
significantly lower fasting and postprandial (2hour) insulin. Factors independently associated 
with DR in multivariate logistic regression analysis were M0, HOMA-B and SG with fasting 
and postprandial (2hour) glucose and insulin. There was no statistical difference in HbA1c, 
systolic blood pressure, AIRG and SI between those with or without DR. 
Principal conclusions: In this cohort of newly diagnosed T2DM subjects DR is associated 
with reduced β-cell responsiveness, resulting from β-cell failure rather than insulin resistance, 
leading to fasting and postprandial hyperglycaemia and hypoinsulinaemia. 
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INTRODUCTION: 
Diabetes Mellitus (DM) is a worldwide epidemic and recent estimates (1) indicate that the 
number of people living with DM is expected to rise from 366 million in 2011 to 552 million 
by 2030, with 90% having Type 2 DM (T2DM). A recent analysis reported that of 
individuals with DM there are approximately 93 million people (~35%) with Diabetic 
Retinopathy (DR), and 28 million with vision-threatening DR (~10%) worldwide (2). In the 
United Kingdom, DR remains a leading cause of blindness in the working age population (3); 
thus early detection and treatment of modifiable risk factors known to influence its onset and 
progression is imperative. After 20 years of known DM duration approximately 40-60% of 
subjects with T2DM have some DR, with 10% of all T2DM subjects having developed sight 
threatening lesions related to proliferative DR and/or exudative maculopathy (4).   
Various risk factors have been associated with the development and progression of DR 
including hyperglycaemia (5), duration of DM (5), hypertension and dyslipidaemia (6-8). The 
UKPDS and DCCT, along with their 10 year follow-up, have demonstrated the benefits of 
early and sustained improvement in glycaemic control with respect to DR (9, 10). 
Furthermore the UKPDS had shown that for every 1% decrease in HbA1c, there was a 37% 
risk reduction in microvascular complications in T2DM, predominantly DR (11). Recently 
the Accord Eye Study Group has shown that intensive glucose and lipid lowering, but not 
intensive blood-pressure control, reduce the rate of progression of DR (12).  
Further analysis of the DCCT study (13) reported that the total glycemic exposure (HbA1C 
and duration of diabetes) was able to explain 11% of the variation in retinopathy risk in the 
complete cohort, but other factors (e.g. environmental, genetic, glycemic variation and other 
measures of glycemia) could explain the remaining variation in risk on their own or through 
an intercorrelation with HbA1C. 
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Investigating the possible association between hyperglycaemia and the presence of DR has 
over the years involved measurement of various metabolic indices, predominantly HbA1C 
and/or fasting plasma glucose (11, 14). In 2005 Shiraiwa et. al. showed that postprandial 
hyperglycaemia and postprandial hypoinsulinemia were possible predictors for incident DR 
in Japanese T2DM subjects who were not on insulin treatment (15). The Diabetes Prevention 
Program (DPP), having studied subjects with impaired glucose tolerance and recent onset 
T2DM, found a higher baseline systolic blood pressure (SBP) and HbA1c amongst those with 
retinopathy, but found no difference in insulin secretion as estimated by the Corrected Insulin 
Response (CIR) (16). In contrast a community based study in Taiwan demonstrated that both 
β-cell dysfunction and insulin resistance (IR) (both measured by the HOMA methodology) 
were associated with DR in established T2DM  patients (17). Similarly, over the last decade, 
there have been other reports associating IR with DR (18-20).  However the relationship 
between β-cell function, glucose effectiveness (SG) and insulin sensitivity (SI) contributing to 
the level of fasting and postprandial dysglycaemia, with the presence of DR in newly 
diagnosed subjects with T2DM remains unreported.  
The aim of this study was to examine the association between β-cell function and insulin 
sensitivity (SI) contributing to various fasting and postprandial glycaemic indices and the 
presence of DR in newly diagnosed and treatment naïve T2DM. 
 
MATERIALS AND METHODS: 
Subjects: 
 A total of 544 newly diagnosed, Caucasian subjects with T2DM were recruited into the study 
within 1-2 weeks after diagnosis of DM prior to any treatment between 1981 and 2007. The 
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subjects were referred by primary care on clinical presentation and were diagnosed by either 
fasting glucose or Oral Glucose Tolerance Test (OGTT) according to WHO criteria (21). No 
formal dietetic or lifestyle advice or anti-diabetic medication was given prior to study 
enrollment.  
Ethical approval was obtained from South Glamorgan/Bro Taf Local Research Ethics 
Committee and all subjects gave informed consent. 
Metabolic Tests: 
All subjects were admitted at approximately 8am to an Investigation Unit following a 12-
hour overnight fast and remained on bed rest throughout the morning of each of the study 
days.  
Basic demographic data i.e. age, sex, height, weight and resting supine blood pressure were 
recorded and BMI calculated. Glycated haemoglobin and total cholesterol were measured. 
All subjects (n=544; Group A) underwent a standardized Meal Tolerance Test (MTT). This 
involved consuming a 500-kcal meal over a 10 minute period (58% carbohydrate, 23% fat, 
and 19% protein) commencing at time 0 min (22). Blood samples were taken from -30 to 240 
minutes at 30 minute intervals, to determine plasma glucose, insulin, and C-peptide 
concentrations.  
From 1991 onwards a subgroup of 201 subjects (Group B) additionally underwent a 
‘Frequently Sampled Intravenous Glucose Tolerance Test’ (FSIVGTT), following a second 
sequential overnight fast.  
The FSIVGTT consisted of baseline blood samples taken at -30, -15 and 0 minutes followed 
by a bolus of glucose (0.3g/kg body weight) given intravenously at 0 minute over a 2 minute 
6 
 
period. Thereafter, blood samples were taken at one minute intervals over 10 minutes. 
Following the intravenous bolus of insulin (Actrapid; Novo Nordisk, Bagsvaerd, Denmark) at 
a dose of 0.05 U/kg insulin given at 20 minutes (22), blood samples were taken at frequent 
intervals up to 180 minutes. At each time point, measurements of plasma glucose and insulin 
were made. 
For both the procedures (MTT and FSIVGTT), an indwelling intravenous cannula was 
inserted into an antecubital fossa vein and connected via a three-way tap to a slow-running 
saline infusion, to maintain the patency of the canula allowing for repeated blood sampling. 
The technique was regularly checked to avoid any dilutional effect of the saline infusion. 
Retinal Photography 
Retinal images were obtained (Canon CR6-45NM) Non-Mydriatic Retinal Camera) through 
dilated pupils. Two 45° images were taken, one centred on the macula and one nasal field per 
eye.  Classification of DR was based on the Diabetic Retinopathy Screening Service for 
Wales grading protocol, which is an enriched version of the UK National DR grading 
protocol (23). The highest grade for both eyes used for classification. All grading was carried 
out by a senior grader from the Diabetic Retinopathy Screening Service for Wales (DRSSW) 
and a diabetologist trained to grade fundus photographs with the DRSSW grading protocol 
and any differences were reconciled by reference to a second diabetologist who was also 
trained to grade fundus photographs.  
Assay methods:  
Duing the metabolic tests blood was withdrawn and placed into tubes containing different 
anti-coagulants;  fluoride/oxalate for glucose and lithium-heparin for measurement of C-
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peptide and specific insulin. Within approximately 10 minutes from collection, the blood 
tubes were spun in a refrigerated centrifuge for 5 minutes at approx 3000 rpm, and the plasma 
aliquoted into labelled tubes and stored frozen at -20°C until assay.  
Glucose was measured by a glucose oxidase assay (YSI 2300, YSI, Hants, UK) and C-peptide 
and specific insulin by immunoassay (24). The within- and between-assay coefficients of 
variation were 1.8% and 1.9%. 5.4% and 8.8%, and 4.1% and 8.8%, respectively for the 
glucose, C-peptide and insulin assays.  
Glycated haemoglobin measurements were performed in a routine Haematology Department.  
HbA1c measurements were determined using a high-performance liquid chromatography 
assay (TOSOH HLC-723 G7; Tosoh Corporation, Tokyo, Japan) (25) which was Diabetes 
Control and Complications Trial (DCCT) aligned and the laboratory participated in an 
external quality assessment scheme. The general assay performance for the HPLC method 
used had a reported coefficients of variation within and between assay of <2.0% (25). HbA1 
measured in the early part of the study by column chromatography was converted to HbA1c 
utilising the formula  (HbA1c = 0.83HbA1 - 0.54)  (26).  
Data analysis:  
Glucose and insulin levels: Fasting plasma glucose (FPG) and fasting plasma insulin (FPI) 
were measured. The postprandial plasma glucose (PPG) and plasma insulin (PPI) were 
represented by the 120 minute values and the areas under the curve AUC(0-240min) for plasma 
glucose and insulin over the 4 hour MTT period were calculated. 
CPR program: The CPR (Calculating Pancreatic Response) program was used to quantify 
pancreatic ß-cell responsiveness during the MTT. M0 (C-peptide response to fasting
 glucose) 
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representing fasting prehepatic insulin secretion and M1 (C-peptide response to postprandial 
glucose) representing the increase in prehepatic insulin secretion in response to an increment 
in postprandial glucose were calculated (27). 
Minimal model analysis: The minimal model analysis of FSIVGTT provided data on SI 
(ability of insulin to enhance the net glucose disappearance from plasma) and SG (ability of 
glucose to promote its own disposal and a marker of insulin-independent component of 
glucose tolerance) (28, 29). The acute insulin response to glucose (AIRG)
 was the incremental 
area under the curve from 0-10 minutes during the FSIVGTT (30). The Disposition Index 
(DI), representing the composite measure of insulin sensitivity and pancreatic ß-cell 
responsiveness, was calculated as DI = SI x AIRG (30).
  
HOMA calculation: HOMA-B, HOMA-S and HOMA-IR were calculated using fasting 
plasma glucose and specific insulin levels using the Homeostasis Model Assessment 
(HOMA; version 2.2.2) (31), utilising fasting concentrations before the MTT. 
Retinopathy Classification: Details of the method of retinal examination and classification of 
DR (23) have previously been described. For the purpose of this study, subjects were divided 
into 2 groups based on the absence (NDR) or presence of any diabetic retinopathy (DR) 
which included Background DR (BDR), Pre-proliferative DR (PPDR), Proliferative DR 
(PDR), possible Maculopathy (M1), and exudative Maculopathy (M2). 
Statistical Analysis: 
Descriptive analyses was conducted with Independent Sample t-test and Mann-Whitney U 
test for continuous variables and the Chi-square test for categorical variables. Normally 
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distributed variables were presented as the mean (±SD) and non-normally distributed 
variables expressed as median (interquartile range).  
The designated putative risk factors were assessed using logistic regression methods with 
non-normally distributed variables [(FPG, FPI, PPG, PPI, AUCGlucose(0-240min), AUCInsulin(0-
240min), HOMA B, M0, M1 and Sg)] log transformed. A non-correlated subset of clinical and 
metabolic variables were determined based on statistical and clinical relevance. All 
multivariate analyses were adjusted for age, gender, BMI and risk factors like systolic blood 
pressure and total cholesterol which have previously been reported to have an association (6-
8) with DR with the final model additionally including parameters of  ß-cell responsiveness/ 
ß-cell function and glycaemia. All analysis were conducted using SPSS 20 with p<0.05 taken 
as statistical significance (two-tailed).  
 
RESULTS: 
Of the 544 subjects (Group A), (393 male and 151 female, 2.6:1) with a mean age of 54 
(SD±10) years, 83.5% (454) had no evidence of DR and 16.5% (90) had evidence of DR at 
presentation. Of those with DR, the majority 84.4% (76) had lesions of BDR (including M1) 
and 15.6% (14) had PPDR; none had either exudative maculopathy or PDR. In the subgroup 
of 201 subjects (Group B) undergoing FSIVGTT in addition to MTT, 85% (171) subjects had 
no evidence of DR at presentation while 15% (30) had DR comprising 12.5% (25) with BDR 
and 2.5% (5) PPDR; none had either exudative maculopathy or PDR.  
Baseline characteristics including age, weight, BMI, systolic and diastolic blood pressure, 
total cholesterol and HbA1c of the patients with DR and NDR in Groups A and B are detailed 
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in Table 1. At baseline, Group A subjects with DR had  significantly  lower body weight at 
diagnosis of DM (p=0.02) compared to those without DR. BMI was also lower in Group A 
and HbA1c was higher although both failed to reach statistical significance. There was no 
significant difference for the remaining baseline characteristics measured between those with 
or without DR. In Group B weight and BMI were lower in those with DR compared to those 
without DR however, this was not significant.  
The metabolic variables measured during the MTT for Group A subjects with either DR or no 
DR are detailed in Table 2. Those with DR had a lower estimated ß-cell responsiveness i.e. 
M0 (p=0.014) and ß-cell
 function (HOMA-B) (p=0.044), associated with higher fasting 
glucose (p=0.021) and lower fasting insulin concentrations (p=0.036). In the postprandial 
state, individuals presenting with DR had higher postprandial (2 hour) glucose (p=0.023) and 
lower postprandial insulin levels (p=0.001). Those with DR had numerically lower but non-
significant (p=0.065) postprandial ß-cell responsiveness [M1{ 13.5 (7.9-23.8) vs 16.9 (9.1-
30.0)*10-9 pmol/kg/min}].  
Over the 4 hour MTT study period, subjects with DR had significantly higher AUCGlucose (0-
240min) (p=0.023) and lower AUCInsulin(0-240 min) (p = 0.001) in comparison to those without DR 
(Table 2). The glucose and insulin profiles and indices of ß-cell responsiveness (M0 and M1) 
during the MTT in subjects with DR and without DR are illustrated in Figures 1a and b.   
The baseline characteristics and the metabolic responses in Group B subjects with either 
NDR or DR who underwent FSIVGTT are detailed in Table 3. Insulin sensitivity (SI) was not 
significantly different between the two groups however, the SG was significantly reduced in 
those with DR compared to those without DR (p=0.012). There was no difference in the 
AIRG and DI between those with or without DR.  
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In  univariate logistic regression analysis postprandial glucose, AUCGlucose (0-240min),  
postprandial insulin, AUCInsulin (0-240min),  M0, HOMA-B and SG were significantly associated 
with the presence of DR (Table 4).  
Factors associated with DR in multivariate logistic regression analyses are detailed in (Table 
4). Measures of ß-cell function M0 (OR 0.66 [95% CI 0. 0.484, 0.894] p=0.007) and  HOMA-
B (OR 0.74 [95% CI 0.570, 0.958] p=0.022) were associated with DR along with SG (OR 
0.20 [95% CI 0.066, 0.602] p=0.004).  
The associtation of fasting glucose (OR 2.23 [95% CI 1.038, 4.791] p=0.04), postprandial 
glucose (OR 2.09 [95% CI 1.063, 4.123] p=0.033), AUCGlucose (0-240min) (OR 2.25 [95% CI 
1.087, 4.664] p=0.029), fasting insulin (OR 0.76 [95% CI 0.585, 0.986] p=0.039), 
postprandial insulin (OR 0.66 [95% CI 0.511, 0.863] p=0.002) and AUCInsulin (0-240min) (OR 
0.61 [95% CI 0.453, 0.828] p=0.001) with the presence of DR at diagnosis of type 2 diabetes 
shows the contribution of fasting, postprandial and overall hyperglycaemic/insulinopaenic 
exposure that leads to the development of DR. However, in this group of subjects there was 
no significant association with HbA1c (OR 2.3 [95% CI 0.900, 5.859] p=0.082) with DR, 
when adjusted for the mentioned variables (age, gender, BMI, systolic blood pressure and 
total cholesterol) though the HbA1c was higher in subjects with DR. Each 1 mmol/L increase 
in fasting and postprandial glucose was associated with a two-fold increase the risk of DR. 
Also each 1 pmol/L decrease in fasting and postptandial insulin was associated with 
increased risk of DR by 24% and 34% respectively.  
In the multivariate logistic regression models once adjusted for glycaemia (using either 
HbA1c/FPG/PPG) in addition to those mentioned above (age, gender, BMI, systolic blood 
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pressure and total cholesterol), ß-cell responsiveness or ß-cell function were the most 
significant risk factors for the presence of DR at diagnosis of diabetes. (Table 5).  
 
DISCUSSION: 
Our findings have shown that the presence of DR is associated with a reduced fasting β-cell 
responsiveness and function. This has resulted in hyperglycaemia in both the fasting and 
postprandial state, concurrent with fasting and postprandial insulinopaenia. In addition the 
insulin-independent component of glucose tolerance was reduced and independently 
associated with the presence of DR at diagnosis.  
In this study, whilst employing both the CPR program (27) and the HOMA methodologies, 
we have established an independent association of M0 and HOMA-B with the presence of DR 
by measuring β-cell function in response to a standardised meal challenge. This relationship 
of DR with β-cell function (HOMA-B) has preiously been analysed in a community-based 
study in Taiwan by Tung et. al. (17), involving patients with T2DM of varying duration, who 
were treated with lifestyle modifications and/or oral hypoglycaemic agents. They observed 
that those subjects with better preserved β-cell function were less likely to have DR. The 
UKPDS has reported that the severity of retinopathy at diagnosis of T2DM was related in 
both sexes to higher fasting plasma glucose levels, higher systolic and diastolic blood 
pressure, lower serum insulin levels, and reduced beta-cell function (32). The association 
between fasting β-cell dysfunction and DR in established T2DM patients as reported by Tung 
et al (17) is also present in our newly-diagnosed, treatment naïve, T2DM subjects. This 
contrasts with the DPP study involving newly diagnosed T2DM subjects, where no difference 
in insulin secretion estimated by the CIR was found (16).   
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We have also shown an independent association for the presence of DR with both fasting and 
postprandial hyperglycaemic and insulinopaenic responses to the MTT, as well as to the 4 
hour (AUC (0-240min)) response to the meal. Thus our study shows both fasting and postprandial 
glycaemic exposure exhibit an independent association with DR. Though HbA1c was higher 
in the subjects with DR the difference narrowly failed to reach significance (p = 0.06). In 
2005 Shiraiwa et.al. studied Japanese T2DM subjects known to have DM but not on insulin 
treatment (15) and established postprandial hyperglycaemia but not HbA1c to independently 
correlate with the presence of DR (15) and stated postprandial hyperglycaemia as a possible 
predictor for incident DR in their subjects. Contrary to our findings two recent studies from 
UK identified an independent association for the presence of DR with HbA1c and SBP in 
newly diagnosed T2DM within the first year of their diagnosis (33, 34). The DPP study 
involving newly diagnosed T2DM subjects has also reported a higher HbA1c amongst those 
with DR (16).  
Glucose effectiveness (SG) represents the capacity of glucose, per se, to enhance glucose 
cellular uptake and to suppress endogenous glucose production  and has been reported to be 
an important determinant of glucose metabolism (35). The glucose transporter protein GLUT-
1 is widely distributed on the plasma membrane of various body tissues contributing an 
important role in insulin-independent glucose uptake (36, 37). Thus, in the presence of 
significant β-cell dysfunction and resultant insulinopaenia, a relatively poor SG will further 
worsen glycaemia. This might explain our findings, where the newly diagnosed T2DM 
subjects with worse SG are more likely to present with DR. 
Our study therefore demonstrates the significant contributions of β-cell dysfunction, fasting 
and postprandial hyperglycaemia/insulinopaenia and reduced glucose effectiveness. Thus it 
adds to the evidence base of co-contributory factors towards development of diabetic 
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complications. Several epidemiological studies have confirmed the association between 
hyperglycaemia and the development of late diabetic complications (9, 38). However most of 
the previous studies have employed the time-averaged mean levels of glycaemia 
measurement of HbA1c as a measure for glycaemic status. Over the last decade there has been 
increasing recognition that HbA1c is not a complete expression of the degree of 
hyperglycaemia and that other aspects of dysglycaemia contribute to the increased risk of 
diabetic complications and  HbA1c was reported to account for 11% of the risk of retinopathy 
in the DCCT (13) . Recent research has also suggested that postprandial glucose levels and 
glucose variability, may confer additional risk for the development of micro- and 
macrovasular diabetic complications (39, 40).   
In our study we measured insulin sensitivity both by the MINMOD program (following 
FSIVGTT) and HOMA (following MTT) and found no difference between T2DM subjects 
presenting with DR compared to those without DR at the time of diagnosis. Our study cohort 
differs from previous reports because it comprised of only newly diagnosed, treatment naïve 
participants with T2DM, and thus lacked the confounding effects of therapeutic interventions. 
By contrast, other cross-sectional studies have associated insulin sensitivity (assessed by 
euglycemic clamp) with the presence or severity of DR (18-20). The numbers of subjects and 
controls in those studies were modest and the subjects recruited had established T2DM that 
was being treated with variety of hypoglycaemic agents, both oral and insulin. It is therefore 
unclear whether the association that they found was entirely independent of the underlying 
confounders such as duration and treatment modalities of DM. Thus in our subjects 
presenting with DR there is no significant contribution from diminished insulin 
sensitivity/resistance at time of clinical diagnosis.  
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The DPP reported that more than 12% of subjects with T2DM had DR within approximately 
3 years of diagnosis (16). 16.5% of our subjects with newly diagnosed T2DM, who presented 
with DR were studied within 1-2 weeks of diagnosis, possibly indicating a slightly longer 
pre-clinical period in our cohort. Whilst our study is limited by its cross sectional design that 
makes it difficult to confirm a cause and effect relationship, the strength of our study lies in 
the recruitment of subjects at clinical diagnosis. Thus, we were able to rule out confounding 
factors such as known duration of DM and treatment modalities, however we do 
acknowledge that duration prior to clinical diagnosis may have been substantial. It also 
presents a detailed analysis of the metabolic response of a T2DM subject emanating from a 
diminished fasting functional β-cell state, resulting in both fasting and postprandial 
dysglycaemia leading to DR but not being affected by an element of insulin 
resistance/sensitivity. 
To summarise, in newly diagnosed treatment-naïve T2DM subjects, the presence of DR is 
associated with relatively worse functional status of both the insulin dependent (as manifested 
by lower β-cell responsiveness with resultant relative insulinopaenia) and insulin independent 
(as manifested by reduced SG) components of glucose tolerance. Thus in this cohort of newly 
diagnosed T2DM subjects, DR is associated with reduced β-cell responsiveness resulting 
from β-cell failure rather than insulin resistance leading to a fasting and postprandial state of 
hyperglycaemia and hypoinsulinaemia.  
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Table 1: Baseline characteristics in subjects with No Diabetic Retinopathy (NDR) compared 
to those with Diabetic Retinopathy (DR) at diagnosis of T2DM. Group A: 544 subjects who 
underwent MTT, Group B: 201 subjects who underwent FSIVGTT 
 
 
  All subjects NDR 
 
DR 
 
p value 
 
Group A Number 544 454 90  
 Age at presentation (years) 54 (10) 54 (10) 56 (11) 0.28 
 Male Sex (%) 393 (72) 324 (71) 69 (77) 0.31 
 Weight (kg) 88 (17) 88 (17) 85 (19) 0.02 
 BMI (kg.m2) 30.2 (5.0) 30.4 (5.3) 29.6 (5.8) 0.06 
 Systolic blood pressure (mmHg) 137 (19) 137 (20) 139 (18) 0.25 
 Diastolic blood pressure (mmHg) 83 (11) 83 (11) 83 (11) 0.71 
 Total Cholesterol (mmol/L) 5.4 (1.2) 5.5 (1.2) 5.2 (1.2) 0.08 
 HbA1c {%} 
            [mmol/mol] 
{7.7}(2.0)   
[61] (22) 
{7.7}(2.0)     
[61] (22) 
{8.0}(1.8)         
[64] (20) 
0.06 
      
Group B Number 201 171 30  
 Age at presentation (years) 55 (10) 55 (10) 55 (11) 0.79 
 Male Sex 145 (72) 125 (73) 20 (67) 0.47 
 Weight (kg) 90 (17) 91 (16.7) 86 (16.5) 0.16 
 BMI (kg.m2) 31.2 (5.5) 31.3 (5.6) 30.6 (4.8) 0.54 
 Systolic blood pressure (mmHg) 135 (19) 135 (18) 134 (19) 0.68 
 Diastolic blood pressure (mmHg) 81 (10) 81 (10) 81 (10) 0.95 
 Total Cholesterol (mmol/L) 5.4 (1.1) 5.4 (1.2) 5.4 (1.0) 0.77 
 HbA1c {%} 
            [mmol/mol] 
{7.6} (1.9)  
[61] (21) 
{7.6}(2.0)     
[61] (22) 
{7.7} (1.5) 
[61] (17) 
 
0.80 
 
Data expressed as Mean (± SD); Sex: Number (%); BMI = Body Mass Index 
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Table 2: Comparison of the metabolic variables during the Meal Tolerance Test in subjects 
with No Diabetic Retinopathy (NDR) and those with Diabetic Retinopathy (DR) at diagnosis 
of T2DM 
 
Group A 
NDR 
(n=454) 
DR 
(n=90) 
p value 
Fasting Glucose (mmol/L) 9.6 (7.6 - 12.7) 10.6 (8.5 – 13.8) 0.021 
Postprandial Glucose (mmol/L) (120 mins)  13.4 (9.8 - 17.3) 15.1 (11.1 - 18.1) 0.023 
AUC Glucose (0-240min) (mmol/L)           11.8 (9.0 – 15.4) 13.6 (9.8 - 16.3) 0.023 
Fasting Insulin (pmol/L) 61.8 (34.0 -99.0) 50.5 (33.9 – 86.36) 0.036 
Postprandial  Insulin (pmol/L) (120 mins)  278.5 (162.0 – 459.3) 189.0 (108.3  –  335.5) 0.001 
AUC Insulin (0-240min) (pmol/L) 199.2 (117.7 - 317.2) 130.5 (83.8-225.7) <0.001 
M0 (*10
-9 pmol/kg/min) 5.3 (3.1-7.8) 3.7 (2.6-7.3) 0.014 
M1 (*10
-9 pmol/kg/min) 16.9 (9.1-30.0) 13.5 (7.9-23.8) 0.065 
HOMA-B (%) 34.9 (19.1-60.3) 26.1 (14.7-48.2) 0.044 
HOMA-S (%) 59.7 (37.7-105.5) 78.7 (45.2-108.6) 0.094 
HOMA-IR 1.7 (0.9-2.7) 1.3 (0.9-2.2) 0.094 
 
Data expressed as median (1st – 3rd Inter Quartile Range)  
AUC = Area Under the Curve 
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Table 3: Comparison of metabolic variables following Frequently Sampled Intravenous 
Glucose Tolerance Test in subjects with No Diabetic Retinopathy (NDR) and those with 
Diabetic Retinopathy (DR) at diagnosis  
 
Group B 
NDR 
(n=171) 
DR 
(n=30) 
p value  
 
SI x 10
-4 [(microU/ml)-1.min-1] 0.8 (0.4-1.4) 0.9 (0.6-1.3) 0.610 
SG x 10
-2 (min–1) 1.4 (1.2-1.7) 1.2 (0.8-1.6) 0.012 
AIRG (0-10min) (microU/ml. min) 111.4 (65.4-177.7) 94.8 (62.2-191.0) 0.703 
DI x 10-2 0.89 (0.39-1.53) 0.82 (0.51-1.70) 0.744 
 
Data expressed as median (1st – 3rd Inter Quartile Range)  
 
SI = Insulin Sensitivity; SG = Glucose effectiveness; AIRG (0-10min) = Acute Insulin Response 
to glucose; DI = Disposition Index   
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Table 4. Univariate and multivariate logistic regression depicting variables independently associated with the presence of DR  
  Number Crude OR (95% CI) p Adjusted OR (95% CI) p OR (95% CI) p  
      (<0.05)  (for age and sex)  (<0.05) (fully adjusted **) (<0.05) 
HbA1c (%) 506 2.329 (0.931, 5.823) 0.071 2.515 (0.997, 6.346) 0.051 2.296 (0.900, 5.859) 0.082 
Fasting Glucose (mmol/L) 544 2.078 (0.982, 4.400) 0.056 2.238 (1.051, 4.765) 0.037 2.23 (1.038, 4.791) 0.040 
Postprandial Glucose (mmol/L) (120 mins)  543 1.944 (1.004, 3.763) 0.049 2.054 (1.058, 3.987) 0.033 2.093 (1.063, 4.123) 0.033 
AUC Glucose (0-240min) (mmol/L)           544 2.081 (1.021, 4.242) 0.044 2.196 (1.075, 4.487) 0.031 2.252 (1.087, 4.664) 0.029 
Fasting Insulin (pmol/L) 494 0.782 (0.607, 1.007) 0.057 0.784 (0.607, 1.012) 0.061 0.759 (0.585, 0.986) 0.039 
Postprandial  Insulin (pmol/L) (120 mins)  534 0.681 (0.526, 0.882) 0.004 0.686 (0.529, 0.890) 0.005 0.664 (0.511, 0.863) 0.002 
AUC Insulin (0-240min) (pmol/L) 534 0.625 (0.465, 0.840) 0.002 0.631 (0.468, 0.850) 0.002 0.612 (0.453, 0.828) 0.001 
M0 (*10
-9 pmol/kg/min) 540 0.693 (0.514, 0.934) 0.016 0.697 (0.517, 0.940) 0.018 0.658 (0.484, 0.894) 0.007 
HOMA-B (%) 494 0.750 (0.582, 0.968) 0.027 0.745 (0.577, 0.963) 0.025 0.739 (0.570, 0.958) 0.022 
SG x 10
-2 (min–1) 201 0.206 (0.069, 0.618) 0.005 0.211 (0.070, 0.642) 0.006 0.200 (0.066, 0.602) 0.004 
 
** for age, sex, BMI, SBP, TCh 
BMI = Body Mass Index, SBP = Systolic Blood Pressure; TCh = Total Cholesterol  
AUC = Area Under the Curve, SG = Glucose effectiveness 
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Table 5. Univariate and Multivariate logistic regression depicting variables independently associated with the presence of DR  
a) Number Crude OR (95% CI) p (<0.05) Adjusted OR (95% CI) p (<0.05) Adjusted OR (95% CI) p (<0.05) 
      
 
(fully adjusted *) 
 
(adjusted for * and HbA1c ʘ)  
M0 (*10
-9 pmol/kg/min) 540 0.693 (0.514, 0.934) 0.016 0.658 (0.484, 0.894) 0.007 0.647 (0.470 – 0.891) 0.008 
HOMA-B (%) 494 0.750 (0.582, 0.968) 0.027 0.739 (0.570, 0.958) 0.022 0.719 (0.550 – 0.940) 0.016 
 b)     
 
(fully adjusted *) 
 
(adjusted for * and FPG ©)  
M0 (*10
-9 pmol/kg/min) 540 0.693 (0.514, 0.934) 0.016 0.658 (0.484, 0.894) 0.007 0.655 (0.482 – 0.891) 0.007 
HOMA-B (%) 494 0.750 (0.582, 0.968) 0.027 0.739 (0.570, 0.958) 0.022 0.739 (0.570 – 0.958) 0.022 
 c)     
 
(fully adjusted *) 
 
(adjusted for * and PPG ®)  
M0 (*10
-9 pmol/kg/min) 540 0.693 (0.514, 0.934) 0.016 0.658 (0.484, 0.894) 0.007 0.655 (0.482 – 0.891) 0.007 
HOMA-B (%) 494 0.750 (0.582, 0.968) 0.027 0.739 (0.570, 0.958) 0.022 0.739 (0.570 – 0.958) 0.022 
 
* for age, sex, BMI, SBP, TCh   ʘ for age, sex, BMI, SBP, TCh, HbA1c 
© for age, sex, BMI, SBP, TCh, FPG  ® for age, sex, BMI, SBP, TCh, PPG 
BMI = Body Mass Index, SBP = Systolic Blood Pressure; TCh = Total Cholesterol, FPG = Fasting Plasma Glucose; PPG = Post Prandial Glucose 
1 
 
9
10
11
12
13
14
15
16
17
-30 0 30 60 90 120 150 180 210 240
m
m
o
l/
L
Time (mins)
Glucose
0
50
100
150
200
250
300
350
400
450
-30 0 30 60 90 120 150 180 210 240
p
m
o
l/
L
Time (mins)
Insulin1a
 
5.3
3.7
0
1
2
3
4
5
6
7
NDR DR
M0
(*
1
0
-9
 p
m
o
l/
kg
/m
in
)
16.9
13.5
0
2
4
6
8
10
12
14
16
18
20
NDR DR
MM1
(*
1
0
-9
p
m
o
l/
kg
/m
in
)
1b
 
Figure: 1 Glucose and Insulin Profiles with β-cell responsiveness in patients with and 
without diabetic retinopathy. 
 1a) Plasma glucose and insulin profile (mean+SEM) during MTT in subjects with NDR 
(Filled square) (n=454) and those with DR (Open triangle) (n=90) at diagnosis of T2DM. 
Significant difference between NDR and DR :  Fasting Glucose (p = 0.021),  
 Postprandial Glucose  (p = 0.023),  Fasting Insulin (p = 0.036) and  Postprandial 
Insulin (p = 0.001).      
 
1b) Fasting (M0) and Post-prandial (M1) β-cell responsiveness during MTT in subjects with 
NDR and those with DR at diagnosis of T2DM
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